Cargando…
Case Report: Circulating Tumor Cells as a Response Biomarker in ALK-Positive Metastatic Inflammatory Myofibroblastic Tumor
Inflammatory myofibroblastic tumors (IMTs) are locally aggressive malignancies occurring at various sites. Surgery is the mainstay of treatment and prognosis is generally good. For children with unresectable or metastatic tumors, however, outcome is particularly severe, limited also by the lack of p...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116882/ https://www.ncbi.nlm.nih.gov/pubmed/33996693 http://dx.doi.org/10.3389/fped.2021.652583 |
_version_ | 1783691492354686976 |
---|---|
author | Bonvini, Paolo Rossi, Elisabetta Zin, Angelica Manicone, Mariangela Vidotto, Riccardo Facchinetti, Antonella Tombolan, Lucia Affinita, Maria Carmen Santoro, Luisa Zamarchi, Rita Bisogno, Gianni |
author_facet | Bonvini, Paolo Rossi, Elisabetta Zin, Angelica Manicone, Mariangela Vidotto, Riccardo Facchinetti, Antonella Tombolan, Lucia Affinita, Maria Carmen Santoro, Luisa Zamarchi, Rita Bisogno, Gianni |
author_sort | Bonvini, Paolo |
collection | PubMed |
description | Inflammatory myofibroblastic tumors (IMTs) are locally aggressive malignancies occurring at various sites. Surgery is the mainstay of treatment and prognosis is generally good. For children with unresectable or metastatic tumors, however, outcome is particularly severe, limited also by the lack of predictive biomarkers of therapy efficacy and disease progression. Blood represents a minimally invasive source of cancer biomarkers for real-time assessment of tumor growth, particularly when it involves the analysis of circulating tumor cells (CTC). As CTCs potentially represent disseminated disease, their detection in the blood correlates with the presence of metastatic lesions and may reflect tumor response to treatment. Herein, we present a case report of a 19-year-old boy with an ALK-positive IMT of the bladder, proximal osteolytic and multiple bilateral lung lesions, who received ALK inhibitor entrectinib postoperatively and underwent longitudinal CTC analysis during treatment. Antitumor activity of entrectinib was demonstrated and was accompanied by regression of lung lesions, elimination of CTCs from the blood and no development of relapses afterwards. Therapy continued without any clinical sign of progression and 24 months since the initiation of treatment the patient remains symptom-free and disease-free. |
format | Online Article Text |
id | pubmed-8116882 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81168822021-05-14 Case Report: Circulating Tumor Cells as a Response Biomarker in ALK-Positive Metastatic Inflammatory Myofibroblastic Tumor Bonvini, Paolo Rossi, Elisabetta Zin, Angelica Manicone, Mariangela Vidotto, Riccardo Facchinetti, Antonella Tombolan, Lucia Affinita, Maria Carmen Santoro, Luisa Zamarchi, Rita Bisogno, Gianni Front Pediatr Pediatrics Inflammatory myofibroblastic tumors (IMTs) are locally aggressive malignancies occurring at various sites. Surgery is the mainstay of treatment and prognosis is generally good. For children with unresectable or metastatic tumors, however, outcome is particularly severe, limited also by the lack of predictive biomarkers of therapy efficacy and disease progression. Blood represents a minimally invasive source of cancer biomarkers for real-time assessment of tumor growth, particularly when it involves the analysis of circulating tumor cells (CTC). As CTCs potentially represent disseminated disease, their detection in the blood correlates with the presence of metastatic lesions and may reflect tumor response to treatment. Herein, we present a case report of a 19-year-old boy with an ALK-positive IMT of the bladder, proximal osteolytic and multiple bilateral lung lesions, who received ALK inhibitor entrectinib postoperatively and underwent longitudinal CTC analysis during treatment. Antitumor activity of entrectinib was demonstrated and was accompanied by regression of lung lesions, elimination of CTCs from the blood and no development of relapses afterwards. Therapy continued without any clinical sign of progression and 24 months since the initiation of treatment the patient remains symptom-free and disease-free. Frontiers Media S.A. 2021-04-29 /pmc/articles/PMC8116882/ /pubmed/33996693 http://dx.doi.org/10.3389/fped.2021.652583 Text en Copyright © 2021 Bonvini, Rossi, Zin, Manicone, Vidotto, Facchinetti, Tombolan, Affinita, Santoro, Zamarchi and Bisogno. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pediatrics Bonvini, Paolo Rossi, Elisabetta Zin, Angelica Manicone, Mariangela Vidotto, Riccardo Facchinetti, Antonella Tombolan, Lucia Affinita, Maria Carmen Santoro, Luisa Zamarchi, Rita Bisogno, Gianni Case Report: Circulating Tumor Cells as a Response Biomarker in ALK-Positive Metastatic Inflammatory Myofibroblastic Tumor |
title | Case Report: Circulating Tumor Cells as a Response Biomarker in ALK-Positive Metastatic Inflammatory Myofibroblastic Tumor |
title_full | Case Report: Circulating Tumor Cells as a Response Biomarker in ALK-Positive Metastatic Inflammatory Myofibroblastic Tumor |
title_fullStr | Case Report: Circulating Tumor Cells as a Response Biomarker in ALK-Positive Metastatic Inflammatory Myofibroblastic Tumor |
title_full_unstemmed | Case Report: Circulating Tumor Cells as a Response Biomarker in ALK-Positive Metastatic Inflammatory Myofibroblastic Tumor |
title_short | Case Report: Circulating Tumor Cells as a Response Biomarker in ALK-Positive Metastatic Inflammatory Myofibroblastic Tumor |
title_sort | case report: circulating tumor cells as a response biomarker in alk-positive metastatic inflammatory myofibroblastic tumor |
topic | Pediatrics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116882/ https://www.ncbi.nlm.nih.gov/pubmed/33996693 http://dx.doi.org/10.3389/fped.2021.652583 |
work_keys_str_mv | AT bonvinipaolo casereportcirculatingtumorcellsasaresponsebiomarkerinalkpositivemetastaticinflammatorymyofibroblastictumor AT rossielisabetta casereportcirculatingtumorcellsasaresponsebiomarkerinalkpositivemetastaticinflammatorymyofibroblastictumor AT zinangelica casereportcirculatingtumorcellsasaresponsebiomarkerinalkpositivemetastaticinflammatorymyofibroblastictumor AT maniconemariangela casereportcirculatingtumorcellsasaresponsebiomarkerinalkpositivemetastaticinflammatorymyofibroblastictumor AT vidottoriccardo casereportcirculatingtumorcellsasaresponsebiomarkerinalkpositivemetastaticinflammatorymyofibroblastictumor AT facchinettiantonella casereportcirculatingtumorcellsasaresponsebiomarkerinalkpositivemetastaticinflammatorymyofibroblastictumor AT tombolanlucia casereportcirculatingtumorcellsasaresponsebiomarkerinalkpositivemetastaticinflammatorymyofibroblastictumor AT affinitamariacarmen casereportcirculatingtumorcellsasaresponsebiomarkerinalkpositivemetastaticinflammatorymyofibroblastictumor AT santoroluisa casereportcirculatingtumorcellsasaresponsebiomarkerinalkpositivemetastaticinflammatorymyofibroblastictumor AT zamarchirita casereportcirculatingtumorcellsasaresponsebiomarkerinalkpositivemetastaticinflammatorymyofibroblastictumor AT bisognogianni casereportcirculatingtumorcellsasaresponsebiomarkerinalkpositivemetastaticinflammatorymyofibroblastictumor |